Current stem cell research & therapy.
Publisher:
Bentham Science Publishers,
Frequency: Eight no. a year, 2016-
Country: United Arab Emirates
Language: English
Start Year:2006 -
ISSN:
1574-888X (Print)
2212-3946 (Electronic)
1574-888X (Linking)
2212-3946 (Electronic)
1574-888X (Linking)
Impact Factor
2.7
| NLM ID: | 101272517 |
| (OCoLC): | 71284563 |
| LCCN: | 2006243983 |
| Classification: | W1 CU81T |
Allogenic mesenchymal stem cells as a treatment for equine degenerative joint disease: a pilot study. Cell-based therapies, such as treatments with mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) are thought to have beneficial effects on the clinical outcome of orthopedic injuries, but very few animal studies with large sample size are published so far. Therefore, the aim of this study was to assess the safety and report the clinical outcome of allogenic, immature or chondrogenic induced MSCs in combination with PRP for the treatment of degenerative joint disease (DJD) in 165 horses. MSCs and PRP were isolated from a 6-year-old donor horse and transplanted either in their native s...
Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients. It has been reported that mesenchymal stem cells (MSCs) have homing capacities and immunomodulating effects after an intravenous injection. However, transplanting MSCs in murine tail veins can result in pulmonary reactions and even death of the animals. Unfortunately, only a few intravenous MSC transplantations have been reported in large animal species and these were performed in a limited number of individuals. To assess the safety of MSC transplantations, a large study on 291 recipient horses is reported here. MSCs were isolated from the peripheral blood (PB) of a 4-year-old and 6-year-old ...